Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Review: Gastric cancer-Clinical aspects.

Venerito M, Link A, Rokkas T, Malfertheiner P.

Helicobacter. 2019 Sep;24 Suppl 1:e12643. doi: 10.1111/hel.12643.

PMID:
31486238
2.

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.

Bornschein J, Wernisch L, Secrier M, Miremadi A, Perner J, MacRae S, O'Donovan M, Newton R, Menon S, Bower L, Eldridge MD, Devonshire G, Cheah C, Turkington R, Hardwick RH, Selgrad M, Venerito M, Malfertheiner P; OCCAMS Consortium, Fitzgerald RC.

Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32384. [Epub ahead of print]

PMID:
31050820
4.

No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study.

Dong J, Gharahkhani P, Chow WH, Gammon MD, Liu G, Caldas C, Wu AH, Ye W, Onstad L, Anderson LA, Bernstein L, Pharoah PD, Risch HA, Corley DA, Fitzgerald RC; Stomach and Esophageal Cancer Study Consortium, Iyer PG, Reid BJ, Lagergren J, Shaheen NJ, Vaughan TL, MacGregor S, Love S, Palles C, Tomlinson I, Gockel I, May A, Gerges C, Anders M, Böhmer AC, Becker J, Kreuser N, Thieme R, Noder T, Venerito M, Veits L, Schmidt T, Schmidt C, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Mayershofer R, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, Jankowski J, Schumacher J, Neale RE, Whiteman DC, Thrift AP.

Clin Gastroenterol Hepatol. 2019 Feb 1. pii: S1542-3565(19)30088-6. doi: 10.1016/j.cgh.2019.01.041. [Epub ahead of print]

PMID:
30716477
5.

Helicobacter pylori Infection: New Facts in Clinical Management.

Malfertheiner P, Venerito M, Schulz C.

Curr Treat Options Gastroenterol. 2018 Dec;16(4):605-615. doi: 10.1007/s11938-018-0209-8. Review.

PMID:
30415359
6.

Gastric cancer: epidemiology, prevention, and therapy.

Venerito M, Vasapolli R, Rokkas T, Malfertheiner P.

Helicobacter. 2018 Sep;23 Suppl 1:e12518. doi: 10.1111/hel.12518. Review.

PMID:
30203589
7.

Evidence for PTGER4, PSCA, and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level.

Heinrichs SKM, Hess T, Becker J, Hamann L, Vashist YK, Butterbach K, Schmidt T, Alakus H, Krasniuk I, Höblinger A, Lingohr P, Ludwig M, Hagel AF, Schildberg CW, Veits L, Gyvyte U, Weise K, Schüller V, Böhmer AC, Schröder J, Gehlen J, Kreuser N, Hofer S, Lang H, Lordick F, Malfertheiner P, Moehler M, Pech O, Vassos N, Rodermann E, Izbicki JR, Kruschewski M, Ott K, Schumann RR, Vieth M, Mangold E, Gasenko E, Kupcinskas L, Brenner H, Grimminger P, Bujanda L, Sopeña F, Espinel J, Thomson C, Pérez-Aísa Á, Campo R, Geijo F, Collette D, Bruns C, Messerle K, Gockel I, Nöthen MM, Lippert H, Ridwelski K, Lanas A, Keller G, Knapp M, Leja M, Kupcinskas J, García-González MA, Venerito M, Schumacher J.

Cancer Med. 2018 Oct;7(10):5057-5065. doi: 10.1002/cam4.1719. Epub 2018 Sep 6.

8.

The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.

Franck C, Rosania R, Franke S, Haybaeck J, Canbay A, Venerito M.

Digestion. 2019;99(2):179-184. doi: 10.1159/000490886. Epub 2018 Sep 4. Review.

PMID:
30179868
9.

Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study.

Rosania R, Von Arnim U, Link A, Rajilic-Stojanovic M, Franck C, Canbay A, Malfertheiner P, Venerito M.

J Gastrointestin Liver Dis. 2018 Jun;27(2):119-125. doi: 10.15403/jgld.2014.1121.272.hpy.

10.

Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection.

Franck C, Hass P, Malfertheiner P, Ricke J, Seidensticker M, Venerito M.

Digestion. 2018;98(2):69-74. doi: 10.1159/000487359. Epub 2018 Apr 26.

PMID:
29698952
11.

Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors.

Venerito M, Schneider C, Costanzo R, Breja R, Röhl FW, Malfertheiner P.

Aliment Pharmacol Ther. 2018 Jun;47(11):1464-1471. doi: 10.1111/apt.14652. Epub 2018 Apr 14.

PMID:
29655196
12.

Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature.

Franck C, Canbay A, Malfertheiner P, Venerito M.

Mol Clin Oncol. 2017 Dec;7(6):1069-1072. doi: 10.3892/mco.2017.1445. Epub 2017 Oct 6.

13.

Recurrent diffuse gastric bleeding as a leading symptom of gastrointestinal AL amyloidosis.

Franck C, Venerito M, Weigt J, Roessner A, Malfertheiner P.

Z Gastroenterol. 2017 Dec;55(12):1318-1322. doi: 10.1055/s-0043-120924. Epub 2017 Dec 6.

PMID:
29212103
14.

Influence of laboratory-related and endoscopy-related factors on the assessment of serum pepsinogens and gastrin-17.

Goni E, Venerito M, Schulz C, Weigt J, Langner C, Link A, Malfertheiner P.

Eur J Gastroenterol Hepatol. 2017 Dec;29(12):1340-1345. doi: 10.1097/MEG.0000000000000952.

PMID:
28984679
15.

Proton-pump inhibitors: understanding the complications and risks.

Malfertheiner P, Kandulski A, Venerito M.

Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):697-710. doi: 10.1038/nrgastro.2017.117. Epub 2017 Sep 20. Review.

PMID:
28930292
16.

Helicobacter pylori, gastric cancer and other gastrointestinal malignancies.

Venerito M, Vasapolli R, Rokkas T, Delchier JC, Malfertheiner P.

Helicobacter. 2017 Sep;22 Suppl 1. doi: 10.1111/hel.12413. Review.

PMID:
28891127
17.

Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions.

Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M.

Gastroenterol Res Pract. 2017;2017:5651903. doi: 10.1155/2017/5651903. Epub 2017 Jul 13. Review.

18.

Helicobacter pylori vacA genotype is a predominant determinant of immune response to Helicobacter pylori CagA.

Link A, Langner C, Schirrmeister W, Habendorf W, Weigt J, Venerito M, Tammer I, Schlüter D, Schlaermann P, Meyer TF, Wex T, Malfertheiner P.

World J Gastroenterol. 2017 Jul 14;23(26):4712-4723. doi: 10.3748/wjg.v23.i26.4712.

19.

Eradication rates in Italian subjects heterogeneously managed for Helicobacter pylori infection. Time to abandon empiric treatments in Southern Europe.

Di Ciaula A, Scaccianoce G, Venerito M, Zullo A, Bonfrate L, Rokkas T, Portincasa P.

J Gastrointestin Liver Dis. 2017 Jun;26(2):129-137. doi: 10.15403/jgld.2014.1121.262.itl.

20.

Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.

Franck C, Malfertheiner P, Venerito M.

BMJ Case Rep. 2017 May 22;2017. pii: bcr-2016-219162. doi: 10.1136/bcr-2016-219162.

21.

Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany - a region at intermediate risk for gastric cancer.

Franck C, Hoffmann A, Link A, Schulz C, Wuttig K, Becker E, Heim M, Venerito M, Malfertheiner P.

Z Gastroenterol. 2017 Jul;55(7):653-656. doi: 10.1055/s-0043-106311. Epub 2017 Apr 24.

PMID:
28437803
22.

Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE.

Wetz C, Apostolova I, Steffen IG, Hofheinz F, Furth C, Kupitz D, Ruf J, Venerito M, Klose S, Amthauer H.

Mol Imaging Biol. 2017 Jun;19(3):437-445. doi: 10.1007/s11307-016-1018-x.

PMID:
27743210
23.

Helicobacter pylori and Gastric Cancer: Timing and Impact of Preventive Measures.

Venerito M, Vasapolli R, Malfertheiner P.

Adv Exp Med Biol. 2016;908:409-18. doi: 10.1007/978-3-319-41388-4_20. Review.

PMID:
27573783
24.

Gastric cancer - clinical and epidemiological aspects.

Venerito M, Link A, Rokkas T, Malfertheiner P.

Helicobacter. 2016 Sep;21 Suppl 1:39-44. doi: 10.1111/hel.12339. Review.

PMID:
27531538
25.

Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.

Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON); Esophageal Adenocarcinoma GenEtics Consortium (EAGLE); Wellcome Trust Case Control Consortium 2 (WTCCC2), Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J.

Lancet Oncol. 2016 Oct;17(10):1363-1373. doi: 10.1016/S1470-2045(16)30240-6. Epub 2016 Aug 12.

26.

[S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease].

Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann JC, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth M; Verantwortlich für die DGVS.

Z Gastroenterol. 2016 Apr;54(4):327-63. German. No abstract available. Erratum in: Z Gastroenterol. 2016 Apr;54(4):1.

PMID:
27512738
27.

Leukotriene receptor expression in esophageal squamous cell cancer and non-transformed esophageal epithelium: a matched case control study.

Venerito M, Helmke C, Jechorek D, Wex T, Rosania R, Antweiler K, Weigt J, Malfertheiner P.

BMC Gastroenterol. 2016 Jul 30;16(1):85. doi: 10.1186/s12876-016-0499-z.

28.

[Prevention, early diagnosis and therapy of gastric cancer].

Venerito M, Vasapolli R, Malfertheiner P.

MMW Fortschr Med. 2016 Jul;158(13):39-43. doi: 10.1007/s15006-016-8513-5. Review. German. No abstract available.

PMID:
27439829
29.

[Sealing of the hepatic resection area using hemostat devices does not improve results of adequate surgery].

Petersen M, Steinert R, Jannasch O, Venerito M, Meissner C, Kropf S, Albrecht R, Lippert H, Meyer F.

Z Gastroenterol. 2016 Jul;54(7):634-41. doi: 10.1055/s-0042-100284. Epub 2016 Jul 18. German.

PMID:
27429100
30.

Nutrition in Patients with Gastric Cancer: An Update.

Rosania R, Chiapponi C, Malfertheiner P, Venerito M.

Gastrointest Tumors. 2016 May;2(4):178-87. doi: 10.1159/000445188. Epub 2016 Apr 13. Review.

31.

[S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease].

Fischbach W, Malfertheiner P, Lynen Jansen P, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann CJ, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth M; Verantwortlich für die DGVS.

Z Gastroenterol. 2016 Apr;54(4):1. doi: 10.1055/s-0035-1567086. Epub 2016 May 11. German.

32.

Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis.

von Arnim U, Wex T, Link A, Messerschmidt M, Venerito M, Miehlke S, Malfertheiner P.

Aliment Pharmacol Ther. 2016 Apr;43(7):825-30. doi: 10.1111/apt.13560. Epub 2016 Feb 22.

33.

Comprehensive epidemiological and genotype-phenotype analyses in a large European sample with idiopathic achalasia.

Becker J, Niebisch S, Ricchiuto A, Schaich EJ, Lehmann G, Waltgenbach T, Schafft A, Hess T, Lenze F, Venerito M, Hüneburg R, Lingohr P, Matthaei H, Seewald S, Scheuermann U, Kreuser N, Veits L, Wouters MM, Gockel HR, Lang H, Vieth M, Müller M, Eckardt AJ, von Rahden BH, Knapp M, Boeckxstaens GE, Fimmers R, Nöthen MM, Schulz HG, Gockel I, Schumacher J.

Eur J Gastroenterol Hepatol. 2016 Jun;28(6):689-95. doi: 10.1097/MEG.0000000000000602.

PMID:
26882171
34.

The Barrett-associated variants at GDF7 and TBX5 also increase esophageal adenocarcinoma risk.

Becker J, May A, Gerges C, Anders M, Schmidt C, Veits L, Noder T, Mayershofer R, Kreuser N, Manner H, Venerito M, Hofer JH, Lyros O, Ahlbrand CJ, Arras M, Hofer S, Heinrichs SK, Weise K, Hess T, Böhmer AC, Kosiol N, Kiesslich R, Izbicki JR, Hölscher AH, Bollschweiler E, Malfertheiner P, Lang H, Moehler M, Lorenz D, Ott K, Schmidt T, Nöthen MM, Hackelsberger A, Schumacher B, Pech O, Vashist Y, Vieth M, Weismüller J, Knapp M, Neuhaus H, Rösch T, Ell C, Gockel I, Schumacher J.

Cancer Med. 2016 May;5(5):888-91. doi: 10.1002/cam4.641. Epub 2016 Jan 18.

35.

Oxyntic gastric atrophy in Helicobacter pylori gastritis is distinct from autoimmune gastritis.

Venerito M, Varbanova M, Röhl FW, Reinhold D, Frauenschläger K, Jechorek D, Weigt J, Link A, Malfertheiner P.

J Clin Pathol. 2016 Aug;69(8):677-85. doi: 10.1136/jclinpath-2015-203405. Epub 2016 Jan 4.

PMID:
26729016
36.

Helicobacter pylori screening: options and challenges.

Venerito M, Goni E, Malfertheiner P.

Expert Rev Gastroenterol Hepatol. 2016;10(4):497-503. doi: 10.1586/17474124.2016.1126507. Epub 2016 Jan 5. Review.

PMID:
26619972
37.

Supportive evidence for FOXP1, BARX1, and FOXF1 as genetic risk loci for the development of esophageal adenocarcinoma.

Becker J, May A, Gerges C, Anders M, Veits L, Weise K, Czamara D, Lyros O, Manner H, Terheggen G, Venerito M, Noder T, Mayershofer R, Hofer JH, Karch HW, Ahlbrand CJ, Arras M, Hofer S, Mangold E, Heilmann-Heimbach S, Heinrichs SK, Hess T, Kiesslich R, Izbicki JR, Hölscher AH, Bollschweiler E, Malfertheiner P, Lang H, Moehler M, Lorenz D, Müller-Myhsok B, Ott K, Schmidt T, Whiteman DC, Vaughan TL, Nöthen MM, Hackelsberger A, Schumacher B, Pech O, Vashist Y, Vieth M, Weismüller J, Neuhaus H, Rösch T, Ell C, Gockel I, Schumacher J.

Cancer Med. 2015 Nov;4(11):1700-4. doi: 10.1002/cam4.500. Epub 2015 Aug 15.

38.

Helicobacter pylori and Gastrointestinal Malignancies.

Venerito M, Vasapolli R, Rokkas T, Malfertheiner P.

Helicobacter. 2015 Sep;20 Suppl 1:36-9. doi: 10.1111/hel.12255. Review.

PMID:
26372823
39.

Adenocarcinomas at different positions at the gastro-oesophageal junction show distinct association with gastritis and gastric preneoplastic conditions.

Bornschein J, Dingwerth A, Selgrad M, Venerito M, Stuebs P, Frauenschlaeger K, Achilleos A, Roessner A, Malfertheiner P.

Eur J Gastroenterol Hepatol. 2015 May;27(5):492-500. doi: 10.1097/MEG.0000000000000299.

PMID:
25822856
40.

Autoimmune gastritis in autoimmune thyroid disease.

Venerito M, Radünz M, Reschke K, Reinhold D, Frauenschläger K, Jechorek D, Di Mario F, Malfertheiner P.

Aliment Pharmacol Ther. 2015 Apr;41(7):686-93. doi: 10.1111/apt.13097. Epub 2015 Feb 3.

41.

Preneoplastic conditions in the stomach: always a point of no return?

Venerito M, Malfertheiner P.

Dig Dis. 2015;33(1):5-10. doi: 10.1159/000369185. Epub 2014 Dec 17. Review.

PMID:
25531491
42.

Gastric cancer--epidemiologic and clinical aspects.

Venerito M, Nardone G, Selgrad M, Rokkas T, Malfertheiner P.

Helicobacter. 2014 Sep;19 Suppl 1:32-7. doi: 10.1111/hel.12164. Review.

PMID:
25167943
43.

[Is mass eradication of Helicobacter pylori infection effective for preventing gastric cancer?].

Venerito M, Malfertheiner P.

Z Gastroenterol. 2014 Jul;52(7):744-5. doi: 10.1055/s-0034-1366273. Epub 2014 Jul 15. German. No abstract available.

PMID:
25026011
44.

Helicobacter pylori infection: selected aspects in clinical management.

Malfertheiner P, Venerito M, Selgrad M.

Curr Opin Gastroenterol. 2013 Nov;29(6):669-75. doi: 10.1097/MOG.0b013e328365d443. Review.

PMID:
24100726
45.

Helicobacter pylori: gastric cancer and extragastric malignancies - clinical aspects.

Venerito M, Selgrad M, Malfertheiner P.

Helicobacter. 2013 Sep;18 Suppl 1:39-43. doi: 10.1111/hel.12078. Review.

PMID:
24011244
46.

Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.

Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P.

Digestion. 2013;88(1):33-45. doi: 10.1159/000350719. Epub 2013 Jul 19. Review.

47.

Helicobacter pylori related and non-related lesions in the stomach.

Venerito M, Wex T, Malfertheiner P.

Minerva Gastroenterol Dietol. 2011 Dec;57(4):395-403. Review.

PMID:
22105728
48.

Serological prevalence of Helicobacter pylori infection in Saxony-Anhalt, Germany, in 2010.

Wex T, Venerito M, Kreutzer J, Götze T, Kandulski A, Malfertheiner P.

Clin Vaccine Immunol. 2011 Dec;18(12):2109-12. doi: 10.1128/CVI.05308-11. Epub 2011 Oct 19.

49.

Helicobacter pylori infection and fundic gastric atrophy are not associated with esophageal squamous cell carcinoma: a case-control study.

Venerito M, Kohrs S, Wex T, Adolf D, Kuester D, Schubert D, Peitz U, Mönkemüller K, Malfertheiner P.

Eur J Gastroenterol Hepatol. 2011 Oct;23(10):859-64. doi: 10.1097/MEG.0b013e3283496469.

PMID:
21811162
50.

Upregulation of leukotriene receptors in gastric cancer.

Venerito M, Kuester D, Harms C, Schubert D, Wex T, Malfertheiner P.

Cancers (Basel). 2011 Aug 8;3(3):3156-68. doi: 10.3390/cancers3033156.

Supplemental Content

Loading ...
Support Center